The FDA approved Fragmin (dalteparin sodium) injection, for subcutaneous use, to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients one month of age and older.
Read more: FDA approves first anticoagulant (blood thinner) for pediatric patients to treat potentially life-threatening blood clots